Pharming Group N.V. PHAR
13.22 USD +0.06 (+0.46%)
At closeNov 10, 2026, 4:00 PM EST
13.22 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
12.89 Day range 13.22
9.11 52-week range 21.18
- YTD
- -25.18%
- 1 year
- -24.67%
News
benzinga.com Pharming Receives U.K. Approval For Joenja In Children Aged 4 To 11 With APDS, Supported By Pediatric Clinical Program Data; Marks Step In Expansion Across Age Groups And Markets Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in…
globenewswire.com MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. MHRA approves Pharming's Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K. Approval extends existing U.K. indication.
fool.com Pharming: 3 Key Takeaways for Long-Term Investors A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.
benzinga.com Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $41 Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $38 to $41.
seekingalpha.com Pharming Group N.V. (PHAR) Q3 2026 Earnings Call Transcript Pharming Group N.V. ( PHAR ) Q3 2026 Earnings Call October 27, 2026 8:30 AM EDT Company Participants Kenneth Lynard - CFO & Co-Chief Executive Officer Leverne Marsh - Co-CEO & Chief Commercial…
marketbeat.com Pharming Group Q3 Earnings Call Highlights Pharming Group NASDAQ: PHAR reported third-quarter revenue growth of 21% to $117.6 million, supported by higher sales of its RUCONEST hereditary angioedema treatment and Joenja therapy for activated…
benzinga.com Pharming Q3 2026 Earnings Call Transcript Pharming (NASDAQ:PHAR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Pharming Affirms FY2026 Sales Guidance of $380.000M-$390.000M vs $383.333M Est Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $380.000 million-$390.000 million to $380.000 million-$390.000 million vs $383.333 million estimate.
benzinga.com Pharming Q3 EPS $0.30 Beats $0.02 Estimate, Sales $117.600M Miss $117.733M Estimate Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.02 by 1400 percent. This is a 200 percent increase over earnings of $0.10 per…
globenewswire.com Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared…
benzinga.com Selective Insurance, Crown Castle, UWM Holdings And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but Selective Insurance surged after beating EPS estimates, approving a $200M buyback and raising its dividend.
benzinga.com Crude Oil Moves Higher; Lockheed Martin Posts Upbeat Earnings U.S. stocks fell, led by a 2% Nasdaq drop; Lockheed Martin beat estimates and raised guidance. Oil rose, while global markets and metals declined.
benzinga.com Healthcare Services Posts Upbeat Q3 Earnings, Joins Pool, Spotify And Other Big Stocks Moving Higher On Thursday U.S. stocks fell, but Healthcare Services Group jumped 8.2% on an earnings beat. Biohaven led gainers, surging 30.5% after FDA news.- benzinga.com Pharming Narrows FY2026 Sales Guidance from $375.000M-$395.000M to $380.000M-$390.000M vs $389.333M Est Pharming (NASDAQ:PHAR) narrows FY2026 sales outlook from $375.000 million-$395.000 million to $380.000 million-$390.000 million vs $389.333 million estimate.
- benzinga.com Pharming Reports Preliminary Q3 Revenues $117.6M, Up 21% YoY; Operating Expenses $74.6M Vs $74.5M YoY; Napazimone FALCON Trial Enrollment Now Expected Complete In First Half 2027, 2026 Revenue Guidance Tightened To $380M-$390M From $375M-$395M Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025Third quarter 2026 total operating expenses of approximately US$74.6 million, in…
globenewswire.com Pharming Group announces third quarter 2026 revenues above market expectations Third quarter 2026 total revenues increase by 21% to approximately US$117.6 million, compared to third quarter 2025 Third quarter 2026 total operating expenses of approximately US$74.6 million, in…
benzinga.com Pharming Says Leniolisib Reduced Spleen Volume In 10 Of 11 Evaluable Participants And Lymph Node Size In All 4 In Phase II Genetic PID Trial, With No New Safety Signals First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was…
globenewswire.com Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026 First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulation Leniolisib was…
seekingalpha.com Pharming Group: Viable Contrarian Buy If Ruconest Stabilizes RUCONEST is Pharming Group's main revenue source today. This asset has already shown a sequential sales rebound that makes me more optimistic. However, RUCONEST still has oral competition that could…
globenewswire.com Pharming announces CEO transition Leiden, the Netherlands, September 29, 2026 : Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the…
globenewswire.com Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS If approved, J oenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval of Joenja for children aged 4 to 11 years with…- benzinga.com HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
globenewswire.com Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026 Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to…
defenseworld.net MAC Alpha Capital Management LP Makes New $29.84 Million Investment in Pharming Group N.V. Sponsored ADR $PHAR MAC Alpha Capital Management LP acquired a new position in Pharming Group N.V. Sponsored ADR (NASDAQ: PHAR) during the undefined quarter, according to the company in its most recent disclosure with…
benzinga.com HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.- benzinga.com Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are…
globenewswire.com FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S. FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kg Newly approved Joenja doses are…
benzinga.com Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11 Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and…
globenewswire.com Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older Leiden, the Netherlands, August 13, 2026: Pharming Group (Euronext Amsterdam: PHARM/Nasdaq: PHAR), today announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric…
prnewswire.com Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
proactiveinvestors.co.uk Ratio makes improved bid for Pharos Energy Ratio Petroleum Energy has raised its recommended offer for Pharos Energy (LSE:PHAR) to 32.8183p per share, trumping a rival bid from Serica Energy PLC (AIM:SQZ) and valuing the company at around…
businesswire.com Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Pharming Group…
gurufocus.com Pharming Group N.V. (PHAR) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (âPharmingâ or the âCompanyâ) (NASDAQ: [url="]PHAR[/url]) inv
businesswire.com Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G. BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) investors concerning the…
businesswire.com Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the…
benzinga.com Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38 Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Nuwellis (NASDAQ:NUWE) stock rose 119.0% to $4.14 during Thursday's pre-market session. GlucoTrack (NASDAQ:GCTK) stock increased by 47.36% to $0.42. The market value of their outstanding…
benzinga.com Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures rise, Meta shares drop 9.4%, Teladoc Health and Rentokil Initial fall after mixed financial results.- benzinga.com Pharming Lowers FY2026 Sales Guidance from $405.000M-$425.000M to $375.000M-$395.000M vs $419.100M Est Pharming (NASDAQ:PHAR) lowers FY2026 sales outlook from $405.000 million-$425.000 million to $375.000 million-$395.000 million vs $419.100 million estimate.
- benzinga.com Pharming Q2 EPS $0.02, Inline, Sales $90.200M Miss $100.625M Estimate Pharming (NASDAQ:PHAR) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 66.67 percent decrease over earnings of $0.06 per share from the same period…
- benzinga.com Pharming Says FDA Accepts Joenja Application for Younger Children Pharming Group ((Euronext: PHARM, NASDAQ:PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com Pharming Affirms FY2026 Sales Guidance of $405.000M-$425.000M vs $421.375M Est Pharming (NASDAQ:PHAR) affirms FY2026 sales outlook from $405.000 million-$425.000 million to $405.000 million-$425.000 million vs $421.375 million estimate.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ: FSLY) down 21.6%, and other stocks decline in pre-market trading.
benzinga.com Why Kulicke And Soffa Industries Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket Shares of Kulicke & Soffa Industries (NASDAQ: VECO) rose after beating earnings estimates. Other gainers include Global Engine, Agilon Health, and Blue Bird Corp.- benzinga.com Pharming Projects FY2026 Total Revenues Of $405M-$425M With 8%-13% Growth Amid Pipeline Investments And Cost Reductions For 2026, the Company anticipates: Total revenues between US$405 million and US$425 million (8% to 13% growth), with quarterly fluctuations expected.Total operating expenses between US$330 million…
- benzinga.com Pharming Q1 EPS $(0.07) Misses $0.01 Estimate, Sales $72.400M Miss $93.750M Estimate Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.01 by 800 percent. This is a 68.18 percent increase over losses of $(0.22) per…
- benzinga.com Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37 Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.
- benzinga.com Pharming's Joenja Edges Closer To Becoming First EU-Approved APDS Treatment After Positive CHMP Opinion With European Commission Decision Due Q2 2026 If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary…